Aptamers in Therapeutics and Diagnostics | Oligonucleotide Applications

Aptamers are single-stranded nucleic acid molecules selected against target compounds through SELEX (Systematic Evolution of Ligands by EXponential enrichment), offering advantages of long shelf life and resistance to denaturation. The SELEX process involves iterative selection rounds where single-stranded DNA libraries bind targets, unbound sequences are removed, and bound sequences are amplified. Commercial aptamers include modifications like thiol groups for electrode attachment. Direct capturing methodology immobilizes aptamers on electrode surfaces while blocking non-specific sites with MCH. Detection relies on electrochemical impedance spectroscopy measuring phase angle shifts and charge transfer resistance (RCT), where increasing analyte concentration produces proportional increases in RCT values.

Aptamer beacons provide one-step diagnostic solutions superior to traditional ELISA assays. Basic designs use hairpin structures with fluorescent tags and quenchers that release fluorescence upon target binding. Advanced versions employ allosteric ribozyme switches where target binding induces conformational changes activating self-cleavage and releasing quenchers. Multi-stage signal amplification systems combine ribozyme-triggered reactions, isothermal amplification, and DNAzyme-catalyzed colorimetric conversion for extreme sensitivity. These platforms translate to lateral flow point-of-care diagnostics compatible with smartphone readers, enabling rapid qualitative and semi-quantitative testing at the bedside.

Aptamer-based biosensors utilize chemically stable, easily synthesized aptamers that form specific secondary structures (such as hairpins) to detect target molecules like bacteria; in the case of Staphylococcus aureus detection, a chimera sequence containing an S. aureus-specific aptamer, endonuclease recognition site, and complementary sequences creates a hairpin structure where the molecular beacon's fluorophore and quencher are brought into proximity, and upon target binding, the hairpin unfolds to release the fluorophore, generating a detectable fluorescent signal that can be amplified through enzymatic reactions.

Biosensors are analytical devices that combine biological recognition elements (such as enzymes, antibodies, or aptamers) with transducers to detect specific targets; aptamers, which are single-stranded oligonucleotides selected through SELEX methodology, offer advantages over antibodies including smaller size, easier functionalization, non-immunogenicity, and the ability to be denatured and renatured, making them valuable for developing low-cost, portable, and selective detection systems for healthcare, environmental monitoring, and food safety applications.

Aptamers are single-stranded DNA/RNA molecules folding into specific 3D structures, invented in the early 1990s. Key advantages include: being ~1/5th the size of antibodies (~30 kDa), enabling better tissue penetration and improved biosensor signals; comparable nanomolar-to-picomolar affinities with superior specificity; ability to discover unknown biomarkers through patient sample comparison; manufacturing costs pennies on the dollar; and exceptional thermal stability allowing denaturation/renaturation. A striking example shows aptamers binding theophylline with 10,000x greater specificity than caffeine despite differing by only a single methyl group. Diagnostic applications include aptamer beacons providing one-step, one-pot reactions replacing multi-hour ELISA protocols, utilizing fluorescent/quencher mechanisms and advanced allosteric ribozyme switches with multi-stage signal amplification achieving remarkable sensitivity. Point-of-care applications using lateral flow test strips compatible with smartphone readers enable qualitative and semi-quantitative diagnostics in resource-limited settings.

The research aimed to develop conjugates between the F23 aptamer and silver nanoparticles. The first question was whether such conjugates could be created, and the second was whether they could distinguish Pseudomonas aeruginosa from closely related species. Using thiol-modified aptamers, researchers successfully created conjugates that showed yellow coloration (indicating nanoparticle presence) and DNA on the nanoparticle surface. Gel electrophoresis confirmed the conjugates had greater negative charge, causing them to migrate differently. This represented a novel approach as no prior work had combined F23 with silver nanoparticles.

Aptamers are small nucleic acid molecules selected through an in vitro SELEX process that offer significant advantages over traditional antibodies in drug development, including smaller size for better tissue penetration, ability to bind small molecules and toxic compounds that cannot be targeted by antibodies, extreme stability for deployment in challenging environments, precise chemical modification capabilities, and zero batch-to-batch variability; these properties enable applications ranging from biomarker discovery and targeted drug delivery to small molecule detection and in vivo imaging, with examples including TLR4-blocking aptamers for stroke treatment, LL-37-targeting aptamers for psoriasis, and aptamer-conjugated nanoparticles for glioblastoma therapy.

Aptamers enable sophisticated targeted drug delivery through conjugation to siRNA, nanoparticles, and chemotherapy drugs. Spherical nucleic acids use 3D DNA structures for efficient membrane crossing. The DNA nanotrain system demonstrates this: targeting aptamer heads connect to multiple drug-carrying 'boxcars' via thermally stable linkers, enabling high drug payloads per aptamer. Preclinical studies showed significant tumor reduction in mouse models. For photodynamic therapy, upconversion nanoparticles solve visible light penetration limitations by absorbing near-infrared light and emitting visible light to activate photosensitizers. Combined with aptamers, these nanoparticles achieve precise targeting through G-quadruplex DNA structures holding photosensitizers and targeting aptamers. Near-infrared excitation generates cytotoxic singlet oxygen near target cells, representing promising deep-tissue cancer treatment approaches.

Aptamers are synthetic oligonucleotides that act as highly specific drug carriers, binding to target proteins on cell surfaces through complementary base pairing and structural conformation to facilitate targeted drug delivery; their binding affinity follows thermodynamic principles where favorable electrostatic interactions compensate for entropy loss, enabling efficient internalization and cargo release within cells.

Aptamers are synthetic DNA or RNA molecules that can be engineered to specifically bind to target proteins, offering advantages over traditional antibodies including smaller size (10^15 times smaller), easier production, lower cost, greater stability, and the ability to be modified for specific medical applications such as targeted drug delivery, tumor imaging, and magnetic nanoparticle-based cellular surgery.

Aptamers serve diverse therapeutic functions: antagonistic aptamers inhibit disease progression (PSMA aptamers reducing metastasis in prostate cancer models at 0.1 mg/kg IV); agonistic aptamers activate immune responses by targeting co-stimulatory receptors (41BB, OX40, CD28), with multimerization switching behavior from antagonist to agonist; aptamers enable drug delivery by conjugating to siRNAs, small molecules, and proteins. Currently, only Macugen (VEGF-165 aptamer) is FDA-approved for age-related macular degeneration. Challenges include nucleic acid degradation (addressed by 2'-fluoro, amino, methyl modifications), renal clearance (aptamers below 30-50 kDa cutoff), and toxicity concerns including non-specific protein binding and PEG-induced immune responses. Multiple aptamers remain in clinical development phases I-III for cancer, inflammation, cardiovascular diseases, and immunological disorders.

Los aptámeros son oligonucleótidos pequeños de ADN o ARN que se unen específicamente a blancos moleculares mediante interacciones débiles, presentando ventajas como alta especificidad, producción química reproducible, buena estabilidad térmica, penetración en tejidos y bajo costo asociado. Se aplican en terapias dirigidas, imagenología molecular, entrega activa de fármacos y detección de toxinas. El método SELEX permite seleccionar aptámeros en aproximadamente 8 semanas, aunque su vida media en plasma es corta, lo que representa un desafío para terapias crónicas. Actualmente solo uno está aprobado por la FDA (pegaptanib para la mácula), pero hay muchos en fases clínicas avanzadas.

Aptamers are small nucleic acid molecules selected via SELEX (Systematic Evolution of Ligands by EXponential enrichment) to bind targets through molecular forces like van der Waals interactions and hydrogen bonding. Starting from 10^15 candidate sequences, iterative rounds of binding, washing, elution, and PCR converge to validated high-affinity binders. Key advantages over antibodies include smaller size enabling better tissue penetration, in vitro selection capability for small molecules and toxic compounds, extreme stability allowing lyophilization, precise chemical modification control, and zero batch-to-batch variability. In drug discovery, aptamers enable novel approaches: selecting against live cells without prior target identification, followed by subtractive selection and proteomics to identify novel biomarkers like peroxiredoxin 4 for gastric cancer. As direct therapeutics, aptamers offer chemical synthesis eliminating contamination risks, small size enabling blood-brain barrier penetration, reduced immunogenicity allowing higher doses, and easy conjugation for drug delivery. Examples include TLR4-blocking aptamers showing reduced ischemic brain injury in stroke models and LL-37-targeting aptamers for psoriasis treatment. Macugen remains the only FDA-approved aptamer drug, with many others advancing through clinical trials for cancers, macular degeneration, and pain management.

The first small nucleic acid drug approved was Vitravene (an antisense oligo) in 1998 for treating CMV infection. To date, 11 antisense oligo drugs have been approved. The first aptamer drug, Macugen, was approved in 2004 for age-related macular degeneration, with only two aptamer drugs approved total. The first siRNA drug, Onpattro, was approved in 2018 for treating neuropathy associated with hereditary transthyretin amyloidosis. Despite siRNAs lagging behind antisense by about 20 years, eight siRNA drugs have been approved, with many approvals occurring in recent years.

The first aptamer drug (Macugen) was approved in 2003 for wet AMD, targeting VEGF inhibition. For approximately 20 years, no new aptamer drugs were approved until Bevacizumab (Avastin) was approved for dry AMD in 2023, marking the first new aptamer drug approval in approximately 20 years. The acquisition of Berkeley Bio by Astellas for approximately 800 billion yen demonstrated the commercial value of novel aptamer therapeutics. Ocular diseases represent ideal targets for aptamer-based therapies due to the closed system preventing systemic drug leakage and small fluid volumes allowing effective treatment with minimal doses. Wet AMD involves abnormal blood vessel growth beneath the retina, leading to leakage of blood and fluid that disrupts retinal structure and causes vision loss. The standard treatment involves VEGF inhibitors, forming the basis of the $1.5 trillion wet AMD treatment market. However, current treatments cannot prevent or reverse fibrosis, and approximately 25% of patients do not respond to initial treatment. FGF2 is involved in both abnormal blood vessel growth and fibrosis formation, making it an attractive dual target. The Phase 2 trial enrolled 86 patients who had received standard VEGF inhibitor treatment but showed inadequate response. Initial Phase 2 results showed RBM007 was not superior to Avastin, causing significant investor concern. However, detailed reanalysis revealed that the initial comparison was flawed due to patient selection bias and changes in drug sensitivity during standard treatment. The reanalysis demonstrated that RBM007 showed equivalent efficacy to Avastin, transforming the initial perceived failure into a successful outcome.